RU2067616C1 - Strain of bacterium bacillus subtilis carrying property antibioticoresistance used for preparation "bactisporin" making - Google Patents
Strain of bacterium bacillus subtilis carrying property antibioticoresistance used for preparation "bactisporin" making Download PDFInfo
- Publication number
- RU2067616C1 RU2067616C1 RU9595105920A RU95105920A RU2067616C1 RU 2067616 C1 RU2067616 C1 RU 2067616C1 RU 9595105920 A RU9595105920 A RU 9595105920A RU 95105920 A RU95105920 A RU 95105920A RU 2067616 C1 RU2067616 C1 RU 2067616C1
- Authority
- RU
- Russia
- Prior art keywords
- strain
- bacillus subtilis
- preparation
- making
- mcm
- Prior art date
Links
- 244000063299 Bacillus subtilis Species 0.000 title claims abstract description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 12
- 230000003115 biocidal effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 abstract description 4
- 208000027244 Dysbiosis Diseases 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 abstract description 2
- 241000588724 Escherichia coli Species 0.000 abstract description 2
- 108010088842 Fibrinolysin Proteins 0.000 abstract description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract description 2
- 108010010803 Gelatin Proteins 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 abstract description 2
- 229930195725 Mannitol Natural products 0.000 abstract description 2
- 229930182555 Penicillin Natural products 0.000 abstract description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 2
- 241000295644 Staphylococcaceae Species 0.000 abstract description 2
- 229920002472 Starch Polymers 0.000 abstract description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 2
- 229930006000 Sucrose Natural products 0.000 abstract description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 2
- 229910021529 ammonia Inorganic materials 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000004202 carbamide Substances 0.000 abstract description 2
- 235000013877 carbamide Nutrition 0.000 abstract description 2
- 239000005018 casein Substances 0.000 abstract description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 2
- 235000021240 caseins Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 229940001501 fibrinolysin Drugs 0.000 abstract description 2
- 235000020932 food allergy Nutrition 0.000 abstract description 2
- 239000008273 gelatin Substances 0.000 abstract description 2
- 229920000159 gelatin Polymers 0.000 abstract description 2
- 235000019322 gelatine Nutrition 0.000 abstract description 2
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 239000003228 hemolysin Substances 0.000 abstract description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 abstract description 2
- 229960005287 lincomycin Drugs 0.000 abstract description 2
- 239000000594 mannitol Substances 0.000 abstract description 2
- 235000010355 mannitol Nutrition 0.000 abstract description 2
- 235000013336 milk Nutrition 0.000 abstract description 2
- 239000008267 milk Substances 0.000 abstract description 2
- 210000004080 milk Anatomy 0.000 abstract description 2
- 150000002823 nitrates Chemical class 0.000 abstract description 2
- 150000002826 nitrites Chemical class 0.000 abstract description 2
- 229940049954 penicillin Drugs 0.000 abstract description 2
- 239000006041 probiotic Substances 0.000 abstract description 2
- 235000018291 probiotics Nutrition 0.000 abstract description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 abstract description 2
- 229960001225 rifampicin Drugs 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 239000008107 starch Substances 0.000 abstract description 2
- 235000019698 starch Nutrition 0.000 abstract description 2
- 229960005322 streptomycin Drugs 0.000 abstract description 2
- 239000005720 sucrose Substances 0.000 abstract description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 241000588769 Proteus <enterobacteria> Species 0.000 abstract 1
- 230000004103 aerobic respiration Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000001888 Peptone Substances 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Изобретение относится к области биотехнологии, в частности к производству лечебно-профилактических препаратов, применяемых при расстройствах желудочно-кишечного тракта, дисбактериозах, ферментной недостаточности органов пищеварения, гнойных инфекциях, пищевой аллергии. The invention relates to the field of biotechnology, in particular the production of therapeutic and prophylactic drugs used for disorders of the gastrointestinal tract, dysbiosis, digestive enzyme deficiency, purulent infections, food allergies.
Известен штамм Bacillus subtilis 534, используемый для получения препарата "Споробактерин", который предназначен для профилактики и лечения заболеваний желудочно-кишечного тракта, дисбактериозов. A known strain of Bacillus subtilis 534, used to obtain the drug "Sporobacterin", which is intended for the prevention and treatment of diseases of the gastrointestinal tract, dysbacteriosis.
Однако известный штамм чувствителен к антибиотикам за исключением полимиксина. Это свойство штамма ограничивает сферу применения препарата при тяжелых формах гнойно-воспалительных заболеваний, лечение которых требует совместного введения бактериального препарата и антибиотика. However, the known strain is sensitive to antibiotics with the exception of polymyxin. This property of the strain limits the scope of the drug for severe forms of purulent-inflammatory diseases, the treatment of which requires the joint administration of a bacterial drug and an antibiotic.
Целью изобретения является создание нового антибиотикоустойчивого штамма для получения препарата вышеуказанного назначения. The aim of the invention is the creation of a new antibiotic-resistant strain to obtain a drug of the above purpose.
Технический результат, получаемый от использования нового штамма выражается в повышении эффективности лечения за счет возможности сочетанного применения бактериального препарата с антибиотиками. Штамм Bacillus subtilis 3Н депонирован в коллекции ГИСК им. Л.А.Тарасевича под N 248. Штамм Bacillus subtilis 3Н получен в результате многократного пересева штамма Bacillus subtilis 534 через питательный агар с возрастающей концентрацией антибиотика. The technical result obtained from the use of the new strain is expressed in increasing the effectiveness of treatment due to the possibility of combined use of a bacterial preparation with antibiotics. The strain Bacillus subtilis 3H deposited in the collection of GISK them. L.A. Tarasevich under N 248. The strain Bacillus subtilis 3H was obtained as a result of repeated reseeding of the strain Bacillus subtilis 534 through nutrient agar with an increasing concentration of the antibiotic.
Штамм Bacillus subtilis 3Н характеризуется следующими свойствами. The strain of Bacillus subtilis 3H is characterized by the following properties.
Культурально-морфологические свойства. Cultural and morphological properties.
Палочки. Величина клеток односуточной агаровой культуры (1,5-4,0)х(0,4-0,6) мкм, часто расположены в цепочках. Клетки окрашиваются положительно по Граму, капсулы не образуют, образуют внутренние центральные споры. Sticks. The size of the cells of a one-day agar culture (1.5-4.0) x (0.4-0.6) microns, often located in chains. Cells stain positively according to Gram, capsules do not form, form internal central spores.
Колонии на мясо-пептонном агаре чаще, шероховатые с фестончатыми краями от белого до серого и бледно-розового оттенков, реже гладкие с ровными краями. Colonies on meat-peptone agar are more often rough with scalloped edges from white to gray and pale pink, less often smooth with smooth edges.
На мясо-пептонном бульоне при 37oС через 18-24 ч образуют пленку на поверхности и придонный осадок.On meat-peptone broth at 37 o C after 18-24 hours form a film on the surface and bottom sediment.
Физиологические признаки. Physiological signs.
Аэроб, оптимальные условия роста при температуре 37oС и рН 6,0-7,5.Aerob, optimal growth conditions at a temperature of 37 o C and a pH of 6.0-7.5.
Биохимические свойства. Biochemical properties.
Расщепляет глюкозу, сахарозу, маннит, мальтозу. Дает положительную реакцию Фогес-Проскауэра на ацетоин. Гидролизует крахмал, казеин, мочевину, пептонизирует молоко, разжижает желатин. Не расщепляет тирозин. Продуцирует каталазу, лецитиназу. Не образует гемолизин и фибринолизин. Восстанавливает нитраты до нитритов. Утилизирует цитрат. Образует аммиак и сероводород, не образует индол. Breaks down glucose, sucrose, mannitol, maltose. Gives a positive reaction of Voges-Proskauer to acetoin. Hydrolyzes starch, casein, urea, peptones milk, liquefies gelatin. Does not break down tyrosine. Produces catalase, lecithinase. Does not form hemolysin and fibrinolysin. Restores nitrates to nitrites. Disposes of citrate. Forms ammonia and hydrogen sulfide, does not form indole.
Антагонистические свойства. Antagonistic properties.
Подавляет рост стафилококков, протея, клебсиелл, кишечной палочки, дрожжевых грибов, стрептококков и синегнойной палочки. It inhibits the growth of staphylococci, protea, Klebsiella, Escherichia coli, yeast fungi, streptococci and Pseudomonas aeruginosa.
Штамм обладает устойчивостью к полимиксину, рифампицину, малочувствителен к пенициллину, линкомицину, стрептомицину. The strain is resistant to polymyxin, rifampicin, insensitive to penicillin, lincomycin, streptomycin.
Сравнительные данные по антибиотикочувствительности и антагонистической активности штаммов Bacillus subtilis 3Н и известного представлены в табл. 1 и 2 (соответственно). Comparative data on the antibiotic sensitivity and antagonistic activity of strains of Bacillus subtilis 3H and known are presented in table. 1 and 2 (respectively).
Данные табл. 1 показывают, что новый штамм обладает высокой антибиотиокоустойчивостью
Как видно из табл. 2, антагонистическая активность штамма Bacillus subtilis 3Н становится более высокой по сравнению с исходным штаммом Bacillus subtilis 534.The data table. 1 show that the new strain has high antibiotic resistance
As can be seen from the table. 2, the antagonistic activity of the strain of Bacillus subtilis 3H becomes higher compared to the original strain of Bacillus subtilis 534.
Использование штамма иллюстрируется следующими примерами. The use of the strain is illustrated by the following examples.
Пример 1. Для выращивания штамма Bacillus subtilis 3Н используют синтетическую среду, содержащую пептон, мальтозу, минеральные соли и микроэлементы. Example 1. To grow a strain of Bacillus subtilis 3H, a synthetic medium containing peptone, maltose, mineral salts and trace elements is used.
Штамм Bacillus subtilis 3Н высевают на матрасы с агаризованной синтетической питательной средой, содержащей пептон, мальтозу, минеральные соли, микроэлементы и помещают в термостат при 37oС на 18-20 ч. Далее смытую с агара культуру засевают в ферментер для подращивания на среде того же состава в объеме 5 л и растят 3-4 ч до достижения культурой фазы экспоненциального роста. Эту культуру используют в качестве посевного материала для засева реактора "Биор" вместимостью 100 л. Выращивание проводят в течение 16-20 ч до перехода культуры в споровую форму. Полученную бактериальную массу концентрируют до (100-120)•109 кл/мл, отмывают от питательной среды стерильным 0,9% -ным раствором хлорида натрия. Разливают в ампулы по (1,0±0,1) мл и высушивают. Полученный препарат назван "Бактиспорин", представляет собой смесь живых вегетативных клеток и спор.The strain Bacillus subtilis 3H is sown on mattresses with an agarized synthetic nutrient medium containing peptone, maltose, mineral salts, trace elements and placed in a thermostat at 37 ° C for 18-20 hours. Next, the agar-washed culture is seeded in a fermenter to grow on the same medium composition in a volume of 5 l and grow 3-4 hours until the culture reaches the phase of exponential growth. This culture is used as seed for inoculation of the Bior reactor with a capacity of 100 liters. Cultivation is carried out for 16-20 hours before the transition of the culture into a spore form. The resulting bacterial mass is concentrated to (100-120) • 10 9 cells / ml, washed from the nutrient medium with a sterile 0.9% sodium chloride solution. Poured into ampoules of (1.0 ± 0.1) ml and dried. The resulting preparation is called "Baktisporin", is a mixture of living vegetative cells and spores.
Препарат "Бактиспорин" безвреден, не содержит посторонней микрофлоры. Остаточная влажность не превышает 3,5% Обладает специфической активностью: количество клеток в одной дозе препарата (1-5)•109 кл/мл, антагонистическая активность (зона задержки роста тестовых штаммов микроорганизмов) составляет 25-40 мм.The drug "Baktisporin" is harmless, does not contain extraneous microflora. Residual humidity does not exceed 3.5%. It has specific activity: the number of cells in one dose of the drug (1-5) • 10 9 cells / ml, antagonistic activity (growth inhibition zone of test strains of microorganisms) is 25-40 mm.
Таким образом, полученный нами штамм может быть использован как производственный для получения препарата из группы пробиотиков, который можно будет применять совместно с антибиотиками. Thus, the strain we obtained can be used as a production strain to obtain a drug from the group of probiotics, which can be used in conjunction with antibiotics.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU9595105920A RU2067616C1 (en) | 1995-04-25 | 1995-04-25 | Strain of bacterium bacillus subtilis carrying property antibioticoresistance used for preparation "bactisporin" making |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU9595105920A RU2067616C1 (en) | 1995-04-25 | 1995-04-25 | Strain of bacterium bacillus subtilis carrying property antibioticoresistance used for preparation "bactisporin" making |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU95105920A RU95105920A (en) | 1996-01-10 |
| RU2067616C1 true RU2067616C1 (en) | 1996-10-10 |
Family
ID=20166822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU9595105920A RU2067616C1 (en) | 1995-04-25 | 1995-04-25 | Strain of bacterium bacillus subtilis carrying property antibioticoresistance used for preparation "bactisporin" making |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2067616C1 (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2169767C1 (en) * | 1999-11-03 | 2001-06-27 | Дочернее предприятие "Биофаг" государственного унитарного предприятия "Иммунопрепарат" | Strain of bacterium bacillus subtilis showing broad spectrum of antagonistic activity and resistance to antibiotics |
| RU2172175C1 (en) * | 1999-12-27 | 2001-08-20 | Дочернее предприятие "Биофаг" государственного унитарного предприятия "Иммунопрепарат" | Curative-prophylactic biopreparation |
| RU2174400C1 (en) * | 2000-05-10 | 2001-10-10 | Государственное унитарное предприятие "Иммунопрепарат" | Bifidobacterium-containing curative-prophylactic preparation |
| RU2176513C1 (en) * | 2000-04-06 | 2001-12-10 | Государственное унитарное предприятие "Иммунопрепарат" | Wound-healing plate |
| RU2182009C1 (en) * | 2000-11-23 | 2002-05-10 | Государственное унитарное предприятие "Иммунопрепарат" | Method for manufacturing probiotic preparations in tablet form |
| RU2184774C1 (en) * | 2001-09-21 | 2002-07-10 | Закрытое акционерное общество "КУЛ" | Strain of bacterium bacillus subtilis used for preparing probiotic preparation designated for prophylaxis and treatment of gastroenteric diseases in animals, poultry and piscine |
| RU2187801C2 (en) * | 2000-07-10 | 2002-08-20 | Пермское научно-производственное объединение "Биомед" | Method of assay of antagonistic activity of probiotics |
| RU2190016C1 (en) * | 2001-06-21 | 2002-09-27 | Всероссийский научно-исследовательский институт ветеринарной санитарии, гигиены и экологии | Strain bacillus firmus used for preparing probiotic preparation designated for prophylaxis and treatment of agriculture animal young stock with bacterial intestine infection |
| RU2193596C2 (en) * | 2000-12-18 | 2002-11-27 | Закрытое акционерное общество "Институт здорового питания" | Strain of bacterium bacillus species izp-04 used as component of ferments for fermented-milk foodstuffs |
| MD20010075A (en) * | 2001-03-22 | 2002-11-30 | Институт Физиологии И Санокреатологии Академии Наук Молдовы | Method of digestive tract sanitation to patients with disbacteriosis |
| RU2215534C2 (en) * | 2002-01-08 | 2003-11-10 | Государственное унитарное предприятие "Иммунопрепарат" | Method for treatment of inflammatory diseases of organs of urinary system |
| RU2229301C1 (en) * | 2002-12-31 | 2004-05-27 | Государственное унитарное предприятие "Иммунопрепарат" | Method for treating purulent-inflammatory diseases in case of diabetes mellitus |
| RU2246537C2 (en) * | 2002-11-11 | 2005-02-20 | Закрытое акционерное общество "КУЛ" | Strain of bacterium bacillus subtilis used for preparing probiotic preparation designated for prophylaxis and treatment of gastroenteric diseases in agricultural animal, poultry and fish |
| RU2278158C2 (en) * | 2004-02-10 | 2006-06-20 | Общество с ограниченной ответственностью "Элест" | Method for production of multifunctional preparation having fungistatic and sorptive activity to decrease of feed, corn, solvent cake and peat-earth toxicity |
| EP0986314B1 (en) * | 1997-06-03 | 2008-09-10 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with sids |
| RU2405821C1 (en) * | 2009-08-04 | 2010-12-10 | Учреждение Российской академии медицинских наук научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН (НИИВС им. И.И. Мечникова РАМН) | 'pashkov' bacillus pumilus bacteria strain producer of biologically active substances exhibiting antagonistic activity on opportunistic, pathogenic bacteria, yeast fungi and viruses |
| RU2497118C1 (en) * | 2012-03-06 | 2013-10-27 | Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии микроорганизмов им. Г.К. Скрябина Российской академии наук (ИБФМ РАН) | FAST METHOD FOR TREATING INTESTINAL SMOOTH MUSCLE CELLS WITH Bacillus cereus HEMOLYSIN II |
| RU2509149C1 (en) * | 2012-08-31 | 2014-03-10 | Общество с ограниченной ответственностью "НОВА" | Bacillus subtilis subsp Subtilis STRAIN HAVING APPARENT ANTAGONISM IN RELATION TO Escherichia coli, Salmonella typhi, Staphylococcus aureus, Listeria monocytogenes AND RESISTANCE TO STREPTOMYCIN AND TETRACYCLINE |
| RU2665547C1 (en) * | 2017-05-17 | 2018-08-30 | Общество с ограниченной ответственностью "Научно-внедренческое предприятие "БашИнком" | Cell-free culture liquid on the basis of the bacillus subtilis, preserving agent for silage and polyfunctional agent for plants with fungicidal, bactericidal and growth promotion properties |
| RU2710783C1 (en) * | 2019-01-29 | 2020-01-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Орловский государственный аграрный университет имени Н.В. Парахина" | Trichoderma atrobrunneum strain having antibacterial activity on bacillus anthracis |
| RU2723411C2 (en) * | 2018-07-13 | 2020-06-11 | Рашит Накипович Кадыров | Bacillus cereus strain rcam04578, a biologically active compounds producer having probiotic properties |
-
1995
- 1995-04-25 RU RU9595105920A patent/RU2067616C1/en active
Non-Patent Citations (1)
| Title |
|---|
| Патент России N 1723116, кл. C 12 N 1/20, 1992. * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0986314B1 (en) * | 1997-06-03 | 2008-09-10 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with sids |
| RU2169767C1 (en) * | 1999-11-03 | 2001-06-27 | Дочернее предприятие "Биофаг" государственного унитарного предприятия "Иммунопрепарат" | Strain of bacterium bacillus subtilis showing broad spectrum of antagonistic activity and resistance to antibiotics |
| RU2172175C1 (en) * | 1999-12-27 | 2001-08-20 | Дочернее предприятие "Биофаг" государственного унитарного предприятия "Иммунопрепарат" | Curative-prophylactic biopreparation |
| RU2176513C1 (en) * | 2000-04-06 | 2001-12-10 | Государственное унитарное предприятие "Иммунопрепарат" | Wound-healing plate |
| RU2174400C1 (en) * | 2000-05-10 | 2001-10-10 | Государственное унитарное предприятие "Иммунопрепарат" | Bifidobacterium-containing curative-prophylactic preparation |
| RU2187801C2 (en) * | 2000-07-10 | 2002-08-20 | Пермское научно-производственное объединение "Биомед" | Method of assay of antagonistic activity of probiotics |
| RU2182009C1 (en) * | 2000-11-23 | 2002-05-10 | Государственное унитарное предприятие "Иммунопрепарат" | Method for manufacturing probiotic preparations in tablet form |
| RU2193596C2 (en) * | 2000-12-18 | 2002-11-27 | Закрытое акционерное общество "Институт здорового питания" | Strain of bacterium bacillus species izp-04 used as component of ferments for fermented-milk foodstuffs |
| MD20010075A (en) * | 2001-03-22 | 2002-11-30 | Институт Физиологии И Санокреатологии Академии Наук Молдовы | Method of digestive tract sanitation to patients with disbacteriosis |
| RU2190016C1 (en) * | 2001-06-21 | 2002-09-27 | Всероссийский научно-исследовательский институт ветеринарной санитарии, гигиены и экологии | Strain bacillus firmus used for preparing probiotic preparation designated for prophylaxis and treatment of agriculture animal young stock with bacterial intestine infection |
| RU2184774C1 (en) * | 2001-09-21 | 2002-07-10 | Закрытое акционерное общество "КУЛ" | Strain of bacterium bacillus subtilis used for preparing probiotic preparation designated for prophylaxis and treatment of gastroenteric diseases in animals, poultry and piscine |
| RU2215534C2 (en) * | 2002-01-08 | 2003-11-10 | Государственное унитарное предприятие "Иммунопрепарат" | Method for treatment of inflammatory diseases of organs of urinary system |
| RU2246537C2 (en) * | 2002-11-11 | 2005-02-20 | Закрытое акционерное общество "КУЛ" | Strain of bacterium bacillus subtilis used for preparing probiotic preparation designated for prophylaxis and treatment of gastroenteric diseases in agricultural animal, poultry and fish |
| RU2229301C1 (en) * | 2002-12-31 | 2004-05-27 | Государственное унитарное предприятие "Иммунопрепарат" | Method for treating purulent-inflammatory diseases in case of diabetes mellitus |
| RU2278158C2 (en) * | 2004-02-10 | 2006-06-20 | Общество с ограниченной ответственностью "Элест" | Method for production of multifunctional preparation having fungistatic and sorptive activity to decrease of feed, corn, solvent cake and peat-earth toxicity |
| RU2405821C1 (en) * | 2009-08-04 | 2010-12-10 | Учреждение Российской академии медицинских наук научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН (НИИВС им. И.И. Мечникова РАМН) | 'pashkov' bacillus pumilus bacteria strain producer of biologically active substances exhibiting antagonistic activity on opportunistic, pathogenic bacteria, yeast fungi and viruses |
| RU2497118C1 (en) * | 2012-03-06 | 2013-10-27 | Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии микроорганизмов им. Г.К. Скрябина Российской академии наук (ИБФМ РАН) | FAST METHOD FOR TREATING INTESTINAL SMOOTH MUSCLE CELLS WITH Bacillus cereus HEMOLYSIN II |
| RU2509149C1 (en) * | 2012-08-31 | 2014-03-10 | Общество с ограниченной ответственностью "НОВА" | Bacillus subtilis subsp Subtilis STRAIN HAVING APPARENT ANTAGONISM IN RELATION TO Escherichia coli, Salmonella typhi, Staphylococcus aureus, Listeria monocytogenes AND RESISTANCE TO STREPTOMYCIN AND TETRACYCLINE |
| RU2665547C1 (en) * | 2017-05-17 | 2018-08-30 | Общество с ограниченной ответственностью "Научно-внедренческое предприятие "БашИнком" | Cell-free culture liquid on the basis of the bacillus subtilis, preserving agent for silage and polyfunctional agent for plants with fungicidal, bactericidal and growth promotion properties |
| RU2723411C2 (en) * | 2018-07-13 | 2020-06-11 | Рашит Накипович Кадыров | Bacillus cereus strain rcam04578, a biologically active compounds producer having probiotic properties |
| RU2710783C1 (en) * | 2019-01-29 | 2020-01-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Орловский государственный аграрный университет имени Н.В. Парахина" | Trichoderma atrobrunneum strain having antibacterial activity on bacillus anthracis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2067616C1 (en) | Strain of bacterium bacillus subtilis carrying property antibioticoresistance used for preparation "bactisporin" making | |
| EP0182315B1 (en) | Novel antibiotic nk84-0218 pharmaceutical compositions containing it and process for the production of the same | |
| RU95105920A (en) | BACTERUS BACTERUS SUBTILIS STRAIN, BEARING ANTIBIOTIC RESISTANCE PROPERTY, USED TO OBTAIN BAKTISPORIN PREPARATION | |
| JPS6320520B2 (en) | ||
| AU615661B2 (en) | Acid urease and production thereof | |
| RU2264454C2 (en) | Biopreparation based on bacteria of genus bacillus for prophylaxis and treatment of various infections and disbiosis, and bacterium strains bacillus subtilis and bacillus licheniformis used in production thereof | |
| Kim et al. | STUDIES ON MIKAMYCIN B LACTONASE I. DEGRADATION OF MIKAMYCIN B BY STREPTOMYCES MITAKAENSIS | |
| Washington et al. | Biochemical and clinical characteristics and antibiotic susceptibility of atypical Enterobacter cloacae | |
| RU2298032C2 (en) | Bacillus subtilis 1719 BACTERIUM STRAIN AS PRODUCER OF ANTAGONISTICALLY ACTIVE BIOMASS IN RELATES TO PATHOGENIC MICROORGANISMS, AS WELL AS PROTEOLYTIC, AMYLOLYTIC, AND LIPOLYTIC ENZYMES | |
| RU2181596C1 (en) | Curative preparation of bacillusstrain bacteria | |
| HU181488B (en) | Process for the hydrolysis of racemic hydantoins into optically active n-carbamoyl-aminoacid derivatives and for preparing the hydrolyzing enzymatic complex | |
| RU2172343C2 (en) | Strain of bacterium bacillus licheniformis showing antiviral and antibacterial activity | |
| US4752469A (en) | Potentiators of beta-lactam antibiotics | |
| RU2193059C2 (en) | Bificine probiotic preparation for calves | |
| Nishiura et al. | Microbial degradation of cephalothin by cephalothin-susceptible Escherichia coli | |
| RU2169767C1 (en) | Strain of bacterium bacillus subtilis showing broad spectrum of antagonistic activity and resistance to antibiotics | |
| RU2081168C1 (en) | Strain of bacterium klebsiella pneumoniae used as reference-strain at enterobacterium hemolysins assay | |
| RU2133272C1 (en) | Strain of bacterium lactobacillus fermentum 90-ts-4(21) used for preparing eubiotic preparation for using in gynecological practice | |
| Loefer | Chloromycetin and growth of certain protozoa | |
| US4264734A (en) | Process for producing antibiotic desacetyl 890A10 | |
| RU2218394C2 (en) | Strain of bacterium lactobacillus acidophilus 27l for preparing biologically active supplements regulating intestine microflora in children of early age | |
| SU1400075A1 (en) | Strain of vibrio cholerae cholerae ogava bacteria used for producing cheloric toxin | |
| HU194310B (en) | Process for preparing alkali metal, alkali earth metal, ammonium salt and n-deacetylated derivative of novel tan-588 antibiotic | |
| JPS6331477B2 (en) | ||
| INOUYE et al. | Structure-activity relationships on the terminal D-amino acid moiety of a novel cephamycin MT-141 |